<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234906</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00013067</org_study_id>
    <nct_id>NCT04234906</nct_id>
  </id_info>
  <brief_title>Prevention of Post-Operative Cardiac Arrhythmias</brief_title>
  <acronym>POCA</acronym>
  <official_title>Multicenter Study for the Prevention of Post-Operative Cardiac Arrhythmias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Moak</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's National Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim 1: Primary Prevention of Post-operative Cardiac Arrhythmias

        1. To evaluate the efficacy of dexmedetomidine vs. the combination of Magnesium Sulfate and
           dexmedetomidine for the prevention of post-operative cardiac arrhythmias in children and
           young adults undergoing open heart surgical repair for congenital or acquired heart
           disease using cardiopulmonary bypass. Dexmedetomidine is currently being administered to
           almost all patients after coming off cardiopulmonary bypass and in the CICU. For this
           aim, the investigator will be comparing dexmedetomidine administered alone or in
           combination with Magnesium Sulfate.

        2. To evaluate medication safety based on the frequency of Serious Adverse Events (SAEs)
           and Adverse Events (AEs)

      Aim 2: Secondary treatment of those Patients that develop a clinically significant arrhythmia
      despite having received either Dexmedetomidine alone or Magnesium Sulfate with
      Dexmedetomidine at the time of cardiac surgery

        1. To evaluate the efficacy of intravenous (IV) Amiodarone vs. IV Procainamide for the
           control of postoperative cardiac arrhythmias developing after the failure of Stage 1,
           Preventative Trial. IV amiodarone and IV procainamide are standardly used treatment
           agents for the treatment of postoperative cardiac arrhythmias in this setting. The
           investigator will be assessing the comparative effectiveness of these agents in
           controlling post-operative cardiac arrhythmias.

        2. To evaluate antiarrhythmic medication safety based on the frequency of SAEs and AEs
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: Postoperative cardiac arrhythmias (POCA) are common in children undergoing
      congenital heart surgery using the heart-lung machine (cardiopulmonary bypass) and have been
      reported in 5-38% of patients. The occurrence of arrhythmias frequently delays the patient's
      postoperative recovery, prolongs Cardiac Intensive Care Unit (CICU) and hospital stay,
      increases costs for hospital care and increases postoperative morbidity and mortality.

      Magnesium Sulfate has been one agent used to reduce the occurrence of postoperative
      arrhythmias. The investigators recently published a propensity-score matched study of the
      intra-operative administration of Magnesium Sulfate revealing that as many as one-third of
      pediatric patients at Children's National Hospital undergoing open-heart surgery using
      cardiopulmonary bypass have postoperative arrhythmias. The use of intraoperative Magnesium
      Sulfate was associated with a reduction in the occurrence of postoperative arrhythmias.
      However, despite the intraoperative use of Magnesium Sulfate there continued to be a fairly
      high residual occurrence rate of post-operative arrhythmias (total arrhythmia frequency
      -18%).

      Dexmedetomidine has also been showed to reduce the occurrence of POCA and has become the
      preferred agent used for post-operative sedation and pain control. In several studies
      reported in the medical literature, dexmedetomidine has been found to decrease the occurrence
      of POCA, like Magnesium Sulfate.

      In this IRB study, the investigator is proposing a clinical study to test if the investigator
      can further decrease the occurrence of postoperative arrhythmias. The investigator will be
      studying if Magnesium Sulfate administrated in conjunction with an intravenous anesthetic
      medication, known as dexmedetomidine, can further decrease the primary occurrence of
      post-operative arrhythmias. The investigator hypothesizes that the effect achieved with the
      simultaneous administration of Magnesium Sulfate and dexmedetomidine will be much greater
      than either medication used alone.

      For those patients who fail preventative medical strategies and develop clinical significant
      post-operative arrhythmias in need of treatment, rescue arrhythmia treatment options include
      the use of potent anti-arrhythmic medications that can have very dramatic effects on the
      patient's heart rate and blood pressure (amiodarone or procainamide). Scant published data
      exists providing us with guidance on the comparative efficacy and safety of these agents in
      the postoperative cardiac surgical patient. The investigator will compare the efficacy and
      adverse effects of the two agents in treating clinically significant arrhythmias that occur
      despite trying to prevent their onset.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Two staged, prospective randomized clinical trial:
Stage 1 targets prevention of post-operative arrhythmias.
Stage 2 allows for re-randomization to secondary treatment for those subjects failing Stage 1, i.e. those patients that develop and require treatment of clinically significant post-operative cardiac arrhythmias with antiarrhythmic medication.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Patients will be randomized within each participating center, not by center, into study groups:
Stage 1: Group 1 - Dexmedetomidine vs. Group 2- Magnesium Sulfate + Dexmedetomidine
Stage 2: If clinically significant arrhythmias in need of treatment develop, patients will be randomized to Group 1 - amiodarone vs. procainamide.
Randomization will occur through a module in Redcap.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Post-Operative Cardiac Arrhythmias</measure>
    <time_frame>3 years</time_frame>
    <description>The investigator will determine the incidence of cardiac arrhythmia in the two study groups (dexmedetomidine and magnesium sulfate). Statistical analysis will be performed to determine whether a statistical difference is detected between the two study groups. The occurrence of cardiac arrhythmias will be determined from continuous cardiac telemetry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Treatment Success Following IV Amiodarone or Procainamide Administration for Post-Operative Cardiac Arrhythmias.</measure>
    <time_frame>3 years</time_frame>
    <description>The investigator will determine treatment success (as measured by the composite of complete or partial arrhythmia control) following the administration of either IV amiodarone or procainamide administration. Percent of treatment success will be determined by the composite success group divided by all given administered each anti-arrhythmic agent. Statistical analysis will be performed to determine whether a statistical difference is detected between the two study groups. Arrhythmia control will be determined from continuous cardiac telemetry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Effects following IV Amiodarone or Procainamide Administration</measure>
    <time_frame>3 years</time_frame>
    <description>The investigator will determine the incidence of adverse effects (hypotension, bradycardia, or low cardiac output) following the administration of either IV amiodarone or procainamide. Statistical analysis will be performed to determine whether a statistical difference is detected between the two study groups.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">870</enrollment>
  <condition>Cardiac; Dysrhythmia, Postoperative</condition>
  <condition>Congenital Heart Surgery</condition>
  <arm_group>
    <arm_group_label>Stage 1, Group 1 - Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine: 1 mcg/kg administered at end of cardiopulmonary bypass, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1, Group 2- Magnesium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2, AMIODARONE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AMIODARONE I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2, PROCAINAMIDE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PROCAINAMIDE IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine: 1 mcg/kg administered over 20 min peri-intubation period, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period</description>
    <arm_group_label>Stage 1, Group 1 - Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day</description>
    <arm_group_label>Stage 1, Group 2- Magnesium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours</description>
    <arm_group_label>Stage 2, AMIODARONE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procainamide</intervention_name>
    <description>IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min</description>
    <arm_group_label>Stage 2, PROCAINAMIDE</arm_group_label>
    <other_name>Pronestyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Any infant, child, adolescent, or young adult with congenital or acquired heart
             disease undergoing open heart surgical repair using cardiopulmonary bypass is eligible
             to be enrolled in this trial.

          -  2) No age, gender or ethnic group restrictions.

        Exclusion Criteria:

          -  1) Non-cardiopulmonary bypass repair of a congenital or acquired cardiac defect.

          -  2) Significant pre-operative arrhythmia history

          -  3) Past history of adverse effect to any of the study medication agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Moak</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey Moak</last_name>
    <phone>2024765707</phone>
    <email>JMOAK@childrensnational.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Litt</last_name>
    <phone>2024765707</phone>
    <email>slitt@childrensnational.org</email>
  </overall_contact_backup>
  <reference>
    <citation>Rekawek J, Kansy A, Miszczak-Knecht M, Manowska M, Bieganowska K, Brzezinska-Paszke M, Szymaniak E, Turska-Kmieć A, Maruszewski P, Burczyński P, Kawalec W. Risk factors for cardiac arrhythmias in children with congenital heart disease after surgical intervention in the early postoperative period. J Thorac Cardiovasc Surg. 2007 Apr;133(4):900-4.</citation>
    <PMID>17382623</PMID>
  </reference>
  <reference>
    <citation>Hoffman TM, Bush DM, Wernovsky G, Cohen MI, Wieand TS, Gaynor JW, Spray TL, Rhodes LA. Postoperative junctional ectopic tachycardia in children: incidence, risk factors, and treatment. Ann Thorac Surg. 2002 Nov;74(5):1607-11.</citation>
    <PMID>12440616</PMID>
  </reference>
  <reference>
    <citation>Dodge-Khatami A, Miller OI, Anderson RH, Goldman AP, Gil-Jaurena JM, Elliott MJ, Tsang VT, De Leval MR. Surgical substrates of postoperative junctional ectopic tachycardia in congenital heart defects. J Thorac Cardiovasc Surg. 2002 Apr;123(4):624-30.</citation>
    <PMID>11986588</PMID>
  </reference>
  <reference>
    <citation>Cecchin F, Johnsrude CL, Perry JC, Friedman RA. Effect of age and surgical technique on symptomatic arrhythmias after the Fontan procedure. Am J Cardiol. 1995 Aug 15;76(5):386-91.</citation>
    <PMID>7639165</PMID>
  </reference>
  <reference>
    <citation>Pfammatter JP, Wagner B, Berdat P, Bachmann DC, Pavlovic M, Pfenninger J, Carrel T. Procedural factors associated with early postoperative arrhythmias after repair of congenital heart defects. J Thorac Cardiovasc Surg. 2002 Feb;123(2):258-62.</citation>
    <PMID>11828284</PMID>
  </reference>
  <reference>
    <citation>Moak JP, Arias P, Kaltman JR, Cheng Y, McCarter R, Hanumanthaiah S, Martin GR, Jonas RA. Postoperative junctional ectopic tachycardia: risk factors for occurrence in the modern surgical era. Pacing Clin Electrophysiol. 2013 Sep;36(9):1156-68. doi: 10.1111/pace.12163. Epub 2013 May 10.</citation>
    <PMID>23662635</PMID>
  </reference>
  <reference>
    <citation>He D, Aggarwal N, Zurakowski D, Jonas RA, Berul CI, Hanumanthaiah S, Moak JP. Lower risk of postoperative arrhythmias in congenital heart surgery following intraoperative administration of magnesium. J Thorac Cardiovasc Surg. 2018 Aug;156(2):763-770.e1. doi: 10.1016/j.jtcvs.2018.04.044. Epub 2018 Apr 18.</citation>
    <PMID>29778339</PMID>
  </reference>
  <reference>
    <citation>He D, Sznycer-Taub N, Cheng Y, McCarter R, Jonas RA, Hanumanthaiah S, Moak JP. Magnesium Lowers the Incidence of Postoperative Junctional Ectopic Tachycardia in Congenital Heart Surgical Patients: Is There a Relationship to Surgical Procedure Complexity? Pediatr Cardiol. 2015 Aug;36(6):1179-85. doi: 10.1007/s00246-015-1141-5. Epub 2015 Mar 12.</citation>
    <PMID>25762470</PMID>
  </reference>
  <reference>
    <citation>Lapsa J, Clark B, Chen YI, Moak JP. Incidence and risk factors for development of post-operative bradyarrhythmias following congenital and acquired cardiac disease repair in pediatric patients. Poster at APS, Baltimore, MD, 2019.</citation>
  </reference>
  <reference>
    <citation>El Amrousy DM, Elshmaa NS, El-Kashlan M, Hassan S, Elsanosy M, Hablas N, Elrifaey S, El-Feky W. Efficacy of Prophylactic Dexmedetomidine in Preventing Postoperative Junctional Ectopic Tachycardia After Pediatric Cardiac Surgery. J Am Heart Assoc. 2017 Mar 1;6(3). pii: e004780. doi: 10.1161/JAHA.116.004780.</citation>
    <PMID>28249845</PMID>
  </reference>
  <reference>
    <citation>Chrysostomou C, Sanchez-de-Toledo J, Wearden P, Jooste EH, Lichtenstein SE, Callahan PM, Suresh T, O'Malley E, Shiderly D, Haney J, Yoshida M, Orr R, Munoz R, Morell VO. Perioperative use of dexmedetomidine is associated with decreased incidence of ventricular and supraventricular tachyarrhythmias after congenital cardiac operations. Ann Thorac Surg. 2011 Sep;92(3):964-72; discussion 972. doi: 10.1016/j.athoracsur.2011.04.099.</citation>
    <PMID>21871284</PMID>
  </reference>
  <reference>
    <citation>Chang PM, Silka MJ, Moromisato DY, Bar-Cohen Y. Amiodarone versus procainamide for the acute treatment of recurrent supraventricular tachycardia in pediatric patients. Circ Arrhythm Electrophysiol. 2010 Apr;3(2):134-40. doi: 10.1161/CIRCEP.109.901629. Epub 2010 Mar 1.</citation>
    <PMID>20194798</PMID>
  </reference>
  <reference>
    <citation>Jian W, Su L, Yiwu L. The effects of magnesium prime solution on magnesium levels and potassium loss in open heart surgery. Anesth Analg. 2003 Jun;96(6):1617-20, table of contents.</citation>
    <PMID>12760983</PMID>
  </reference>
  <reference>
    <citation>Manrique AM, Arroyo M, Lin Y, El Khoudary SR, Colvin E, Lichtenstein S, Chrysostomou C, Orr R, Jooste E, Davis P, Wearden P, Morell V, Munoz R. Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: a randomized controlled study. J Thorac Cardiovasc Surg. 2010 Jan;139(1):162-169.e2. doi: 10.1016/j.jtcvs.2009.07.064. Epub 2009 Oct 12.</citation>
    <PMID>19819469</PMID>
  </reference>
  <reference>
    <citation>Dittrich S, Germanakis J, Dähnert I, Stiller B, Dittrich H, Vogel M, Lange PE. Randomised trial on the influence of continuous magnesium infusion on arrhythmias following cardiopulmonary bypass surgery for congenital heart disease. Intensive Care Med. 2003 Jul;29(7):1141-4. Epub 2003 May 28.</citation>
    <PMID>12774159</PMID>
  </reference>
  <reference>
    <citation>Lee HY, Ghimire S, Kim EY. Magnesium supplementation reduces postoperative arrhythmias after cardiopulmonary bypass in pediatrics: a metaanalysis of randomized controlled trials. Pediatr Cardiol. 2013 Aug;34(6):1396-403. doi: 10.1007/s00246-013-0658-8. Epub 2013 Feb 27. Review.</citation>
    <PMID>23443885</PMID>
  </reference>
  <reference>
    <citation>Dorman BH, Sade RM, Burnette JS, Wiles HB, Pinosky ML, Reeves ST, Bond BR, Spinale FG. Magnesium supplementation in the prevention of arrhythmias in pediatric patients undergoing surgery for congenital heart defects. Am Heart J. 2000 Mar;139(3):522-8.</citation>
    <PMID>10689268</PMID>
  </reference>
  <reference>
    <citation>Verma YS, Chauhan S, Gharde P, Lakshmy R, Kiran U. Role of magnesium in the prevention of postoperative arrhythmias in neonates and infants undergoing arterial switch operation. Interact Cardiovasc Thorac Surg. 2010 Nov;11(5):573-6. doi: 10.1510/icvts.2010.239830. Epub 2010 Aug 5.</citation>
    <PMID>20688775</PMID>
  </reference>
  <reference>
    <citation>Fairley JL, Zhang L, Glassford NJ, Bellomo R. Magnesium status and magnesium therapy in cardiac surgery: A systematic review and meta-analysis focusing on arrhythmia prevention. J Crit Care. 2017 Dec;42:69-77. doi: 10.1016/j.jcrc.2017.05.038. Epub 2017 Jun 21. Review.</citation>
    <PMID>28688240</PMID>
  </reference>
  <reference>
    <citation>Li X, Zhang C, Dai D, Liu H, Ge S. Efficacy of dexmedetomidine in prevention of junctional ectopic tachycardia and acute kidney injury after pediatric cardiac surgery: A meta-analysis. Congenit Heart Dis. 2018 Sep;13(5):799-807. doi: 10.1111/chd.12674. Epub 2018 Sep 27.</citation>
    <PMID>30260073</PMID>
  </reference>
  <reference>
    <citation>Gautam NK, Turiy Y, Srinivasan C. Preincision Initiation of Dexmedetomidine Maximally Reduces the Risk of Junctional Ectopic Tachycardia in Children Undergoing Ventricular Septal Defect Repairs. J Cardiothorac Vasc Anesth. 2017 Dec;31(6):1960-1965. doi: 10.1053/j.jvca.2017.04.010. Epub 2017 Apr 10.</citation>
    <PMID>28774644</PMID>
  </reference>
  <reference>
    <citation>Mahmoud AB, Tantawy AE, Kouatli AA, Baslaim GM. Propranolol: a new indication for an old drug in preventing postoperative junctional ectopic tachycardia after surgical repair of tetralogy of Fallot. Interact Cardiovasc Thorac Surg. 2008 Apr;7(2):184-7. Epub 2007 Dec 18.</citation>
    <PMID>18089616</PMID>
  </reference>
  <reference>
    <citation>Shuplock JM, Smith AH, Owen J, Van Driest SL, Marshall M, Saville B, Xu M, Radbill AE, Fish FA, Kannankeril PJ. Association between perioperative dexmedetomidine and arrhythmias after surgery for congenital heart disease. Circ Arrhythm Electrophysiol. 2015 Jun;8(3):643-50. doi: 10.1161/CIRCEP.114.002301. Epub 2015 Apr 15.</citation>
    <PMID>25878324</PMID>
  </reference>
  <reference>
    <citation>Amrousy DE, Elshehaby W, Feky WE, Elshmaa NS. Safety and Efficacy of Prophylactic Amiodarone in Preventing Early Junctional Ectopic Tachycardia (JET) in Children After Cardiac Surgery and Determination of Its Risk Factor. Pediatr Cardiol. 2016 Apr;37(4):734-9. doi: 10.1007/s00246-016-1343-5. Epub 2016 Jan 27.</citation>
    <PMID>26818850</PMID>
  </reference>
  <reference>
    <citation>Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 1988 Mar;44(1):229-41. Erratum in: Biometrics 1988 Sep;44(3):923.</citation>
    <PMID>3358991</PMID>
  </reference>
  <reference>
    <citation>Lakatos E. Designing complex group sequential survival trials. Stat Med. 2002 Jul 30;21(14):1969-89.</citation>
    <PMID>12111882</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's National Research Institute</investigator_affiliation>
    <investigator_full_name>Jeffrey Moak</investigator_full_name>
    <investigator_title>Director, Electrophysiology and Pacing, Principle Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Magnesium Sulfate</keyword>
  <keyword>Dexedetomidine</keyword>
  <keyword>anti-arrhythmic medications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Procainamide</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

